Literature DB >> 11805201

Angiotensin I-converting enzyme inhibition increases cardiac catecholamine content and reduces monoamine oxidase activity via an angiotensin type 1 receptor-mediated mechanism.

Walter Raasch1, Torsten Bartels, Annabella Gieselberg, Andreas Dendorfer, Peter Dominiak.   

Abstract

Antihypertensive and cardioprotective effects of angiotensin I-converting enzyme (ACE) inhibitors are well established and have usually been attributed to the inhibition of angiotensin II (ANG)-mediated effects at vascular or ventricular (angiotensin type 1) AT(1) receptors. One other important mechanism involves ANG-induced interactions with the sympathetic nervous system, which might include alterations of cardiac catecholamine concentrations during ACE inhibition due to a modulation of monoamine oxidase (MAO) activity. Tissue catecholamines were studied in spontaneously hypertensive rats that were long-term treated with captopril (50 or 0.5 mg/kg/day), enalapril (10 or 0.1 mg/kg/day), an AT(1) receptor antagonist (candesartan-cilexetil, 3 mg/kg/day), or a calcium antagonist (mibefradil, 18 mg/kg/day). The kinetic parameters of MAO were then determined in vitro in the presence of ANG, captopril, enalaprilat, or candesartan. Noradrenaline and adrenaline contents were doubled in the left ventricle by captopril, enalapril, or candesartan independently of hypotensive potency but not in liver or cortex. In parallel, cardiac MAO activity was reduced by all doses of captopril (49/29%), enalapril (52/24%), or candesartan (38%). Mibefradil, which does not interact with the renin-angiotensin system, did not alter cardiac catecholamines or MAO activity when an equipotent antihypertensive dose was applied. In vitro MAO activity was not influenced by ANG, enalaprilat, or captopril at concentrations of up to 1 mM. It is concluded that diminished AT(1) receptor stimulation decreases cardiac MAO activity, probably by regulating MAO expression, since ANG, ACE inhibitors, and AT(1) antagonists had no effect on MAO activity in vitro. This action contributes to an increase in cardiac catecholamine content that may improve cardiac sympathetic control during therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11805201     DOI: 10.1124/jpet.300.2.428

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  5 in total

1.  Allosteric modulation of semicarbazide-sensitive amine oxidase activities in vitro by imidazoline receptor ligands.

Authors:  Andrew Holt; Barbara Wieland; Glen B Baker
Journal:  Br J Pharmacol       Date:  2004-09-27       Impact factor: 8.739

2.  Noninvasive detection of risk for emotion-provoked myocardial ischemia.

Authors:  Matthew M Burg; Brendon Graeber; Aseem Vashist; Dorothea Collins; Christine Earley; Joyce Liu; Rachel Lampert; Robert Soufer
Journal:  Psychosom Med       Date:  2008-10-21       Impact factor: 4.312

3.  Myocardial gene expression of matched hibernating and control tissue from patients with ischemic left ventricular dysfunction.

Authors:  Dietlind Zohlnhöfer; Thomas G Nührenberg; Felix Haas; Frank Bengel; Albert Schömig; Patrick A Baeuerle; Markus Schwaiger
Journal:  Heart Vessels       Date:  2008-07-23       Impact factor: 2.037

Review 4.  Monoamine Oxidase-Related Vascular Oxidative Stress in Diseases Associated with Inflammatory Burden.

Authors:  Adrian Sturza; Călin M Popoiu; Mihaela Ionică; Oana M Duicu; Sorin Olariu; Danina M Muntean; Eugen S Boia
Journal:  Oxid Med Cell Longev       Date:  2019-04-15       Impact factor: 6.543

5.  Commentary: 3-Iodothyronamine Reduces Insulin Secretion In Vitro via a Mitochondrial Mechanism.

Authors:  Annunziatina Laurino; Laura Raimondi
Journal:  Front Endocrinol (Lausanne)       Date:  2018-02-28       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.